Bicara Therapeutics Inc’s recently made public that its Director RA CAPITAL MANAGEMENT, L.P. acquired Company’s shares for reported $32.99 million on Sep 16 ’24. In the deal valued at $18.00 per share,1,833,000 shares were bought. As a result of this transaction, RA CAPITAL MANAGEMENT, L.P. now holds 4,303,418 shares worth roughly $55.86 million.
Then, Flynn James E bought 70,000 shares, generating $1,260,000 in total proceeds. Upon buying the shares at $18.00, the Possible Members of 10% Group now owns 897,587 shares.
Wedbush initiated its Bicara Therapeutics Inc [BCAX] rating to an Outperform in a research note published on February 06, 2025; the price target was $31. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in early December with a ‘”a Buy”‘ rating. Rodman & Renshaw began covering BCAX with “Buy” recommendation on November 05, 2024. TD Cowen started covering the stock on October 08, 2024. It rated BCAX as “a Buy”.
Price Performance Review of BCAX
On Friday, Bicara Therapeutics Inc [NASDAQ:BCAX] saw its stock fall -0.15% to $12.98. Over the last five days, the stock has lost -3.71%. Bicara Therapeutics Inc shares have fallen nearly -25.49% since the year began.
Levels Of Support And Resistance For BCAX Stock
The 24-hour chart illustrates a support level at 12.31, which if violated will result in even more drops to 11.64. On the upside, there is a resistance level at 13.67. A further resistance level may holdings at 14.37. The Relative Strength Index (RSI) on the 14-day chart is 45.91, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.30, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 51.80%. Stochastics %K at 58.51% indicates the stock is a holding.
The most recent change occurred on October 08, 2024 when Stifel began covering the stock and recommended ‘”a Buy”‘ rating along with a $47 price target.
